InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,868.40
(
-0.79%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
87.10
(
-0.14%
)
Bitcoin
64,322.90
(
0.06%
)
Post# of 251589
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

rwdm

Send PM Follow Ignore
Followers 1
Posts 132
Boards Moderated 0
Alias Born 07/19/2010

rwdm

Re: None

Thursday, 07/29/2010 2:07:10 PM

Thursday, July 29, 2010 2:07:10 PM

Post# of 251589
The estimated patent date of Remicade and Rituxan in Europe are 2014 and 2015 respectively. In the US both expiry dates are in 2018. Is this because of Genentech's Cabily patent? If yes, does this mean that the expiry date of most of the mabs in US is 2018?

Is Teva's Rituximab TL011, which is starting nowadays clinical trials, in the regulatory pathway of BLA or as a biosimilar?
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up